Introduction WHO ECDD Questionnaire: Cannabidiol (CBD) · Nomenclature Regulations 1967, etc.), the...

This is one of five questionnaires that Member States are invited to complete ahead of the 40thWHO Expert Committee on Drug Dependence. This questionnaire will ask you about extracts andtinctures containing cannabidiol (CBD).

--------------------------------------------------------------------------------------------------

The questionnaire will take about 15-25 minutes to complete. You may return to the questionnaireto amend your responses at any time until the closure of the questionnaire.

To commence the questionnaire, you will first be asked to indicate that you agree to WHO datasharing policy. The responses of this questionnaire will be compiled into a report that will bepublicly available on the WHO ECDD website. The name of your country may be presentedalongside questionnaire data unless you indicate that you wish for your country name to beanonymised in the final report.

If you wish to submit any information to the attention of the ECDD Secretariat, you will be invited toupload documents at the end of the questionnaire.

We thank you in advance for taking the time to complete this questionnaire.

Introduction

WHO ECDD Questionnaire: Cannabidiol (CBD)

General Information


Name

1. Focal point contact details*

2. Please indicate your country*

Statement of policy on data sharing Data are the basis for all sound public health actions and the benefits of data sharing are widelyrecognized, including scientific and public health benefits. Whenever possible, WHO wishes topromote the sharing of health data, including but not restricted to surveillance and epidemiologicaldata.

In this connection, and without prejudice to information sharing and publication pursuant to legallybinding instruments, by providing data to WHO, the [Ministry of Health][other responsiblegovernmental entity] of [Country]:

Confirms that all data to be supplied to WHO (including but not limited to the types listed in Annex3) hereunder have been collected in accordance with applicable national laws, including dataprotection laws aimed at protecting the confidentiality of identifiable persons;

Agrees that WHO shall be entitled, subject always to measures to ensure the ethical and secure useof the data, and subject always to an appropriate acknowledgement of [Country]:

- to publish the data, stripped of any personal identifiers (such data without personal identifiersbeing hereinafter referred to as “the Data”) and make the Data available to any interested party onrequest (to the extent they have not, or not yet, been published by WHO) on terms that allow non-commercial, not-for-profit use of the Data for public health purposes (provided always thatpublication of the Data shall remain under the control of WHO);

- to use, compile, aggregate, evaluate and analyse the Data and publish and disseminate the resultsthereof in conjunction with WHO’s work and in accordance with the Organization’s policies andpractices.

Except where data sharing and publication is required under legally binding instruments (IHR, WHONomenclature Regulations 1967, etc.), the [Ministry of Health][other responsible governmentalentity] of [Country] may in respect of certain data opt out of (any part of) the above, by notifyingWHO thereof in writing at the following address, provided that any such notification shall clearlyidentify the data in question and clearly indicate the scope of the opt-out (in reference to the above), and provided that specific reasons shall be given for the opt out.

[email protected]

WHO Data Sharing Policy


3. Please confirm that you agree*

I agree for the information provided in this questionnaire to be published in a report

General cannabis information


4. Do you have any information about the use of CBD for any purpose (including medical or non-medicaluse) in your country?

*

Yes

No - you will be directed to the end of the questionnaire

This page will ask you about approved medical use of CBD.

Medical use


5. At national level, is CBD legally approved for medical use in your country?*

Yes

No

Other (please specify)

Medical use: Therapeutic indications


6. Please indicate any approved therapeutic indications for the use of CBD in your country

Epilepsy

Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury

Arthritis

Dystonia

Huntington’s disease

Parkinson’s disease

Tourette’s syndrome

Glaucoma

Anxiety

Depression

PTSD

Schizophrenia /psychosis

Alzheimer’s disease/ dementia

Skin disease

Irritable bowel syndrome

Inflammatory bowel disease

Liver disease

Obesity/ diabetes

Cancer

HIV/AIDS

Chronic pain

Crohn's disease

Attention Deficit Disorder (ADD)

None specified


7. Please indicate any symptoms that CBD is approved to treat

Acute pain

Chronic non-cancer pain

Cancer pain

Nausea/ vomiting

Appetite stimulant

Headaches/ migraines

Muscle spasms

Seizures

Sleep problems

Alcohol withdrawal symptoms

Opioid withdrawal symptoms

Palliative care


Name of marketed product& CBD /THC content (ifknown):





8. Please indicate whether there are any permitted marketed products of CBD.

9. Are there any ongoing approved clinical trials in your country that are developing CBD for medicaluse?

Yes

No


Product name

Product name

Product name

Product name

Product name

Product name

10. Please indicate product name/ trial number/ study phase of any ongoing trials that are developingproducts of CBD for medical use

Medical use: Access


11. Do individuals require a prescription to obtain medical CBD?

Yes

No

N/A


12. What types of professionals are allowed to prescribe CBD?

Medical doctor / psychiatrist

Osteopath

Nurse/nurse prescriber

Pharmacist

Psychologist

Physiotherapist

Healthcare worker

No prescription is required


13. What kinds of settings are approved to legally dispense CBD in your country?

At a doctor's office

Pharmacies

Online

Retail shops

Licensed/specialised cannabis dispensaries

Hospitals

Outpatient clinics

Palliative care facilities

Nursing homes


14. If patients use medical CBD on prescription or recommendation of a health professional, will they bereimbursed for the costs of their medication?

Yes, they will be reimbursed by National Health Services

Yes, each health insurance company in the country will reimburse the patients

Some health insurances do reimburse for the costs, others do not

Patients have to make extra health insurance arrangements to be reimbursed

No, patients cannot be reimbursed


15. Are any clinical guidelines used in your country for the prescribing of medical CBD?

No

N/A

Yes (please specify)

16. Is there a regulatory agency in your country that monitors CBD for medical use?

No

N/A


The number hassubstantially

increased

The number hasslightly

increased

The number hasremained the

sameThe number hasslightly reduced

The number hassubstantially

reducedDon't know/

unsure

CBD

17. How would you describe the trend in the number of users of CBD for medical use over the last 3 years?

This section will ask about the general policies in your country towards cannabis-relatedsubstances for medical use

Medical use: National legislation


Yes, my country has changed its legislation No, my country has not changed its legislation

CBD

Unknown/ Other (please specify)

18. In the past 3 years, has your country changed its national legislation around access to cannabis-related substances for medical use?

19. If yes, what types of legislative changes has your country made for medical use of CBD?

Change to the legal status of medical cannabis

Changes to the supply of medical cannabis (e.g. changes in licensing, import – or export of products)

Changes to access to medical cannabis (e.g. variety in products, therapeutic indications etc)


Yes, my country is preparing changes in its

legislationNo, my country is not preparing changes in its

legislation

CBD

Unknown/ Other (please specify)

20. Is your country currently considering changes to its national legislation around access to cannabis andcannabis-related substances for medical use?

There would be /hasbeen a

substantially negativeimpact on public

health

There wouldbe /has been a

slightlynegativeimpact on

public health

There wouldbe/ has beenno impact onpublic health

There wouldbe/ has been aslightly positive

impact onpublic health

There would be/ hasbeen a

substantially positiveimpact on public

healthDon't know/

unsure

Increased availabilityfor medical use

Decreased availabilityfor medical use

Please explain your response:

21. In your opinion, how do you feel the changed legislation around access to CBD for medical usewould impact / has impacted public health in your country?

The next section will ask you about non-medical use of CBD in your country. Non-medical useincludes both recreational use, and use for self-medication purposes.

Non-medical Use


22. On a national level, is CBD legally available for non-medical use in your country?*

Yes

No


23. Is CBD used for cultural, ceremonial, or religious purposes in your country?

No

Unknown


24. Does your country collect prevalence data around the use of CBD?

Yes

No

N/A

Unknown

Prevalence of non-medical cannabis use


Number (or % ofpopulation) used in lifetime

Number (or % ofpopulation) used in the lastyear

Number (or % ofpopulation) used in thepast month

Year of survey data

Prevalence by age group(if known)

25. Prevalence of use of CBD amongst adults ( over 18 years of age)

Number (or % ofpopulation) used in lifetime

Number (or % ofpopulation) used in the lastyear

Number (or % ofpopulation) used in thepast month

Year of survey data

Prevalence data by agegroup (if available)

26. Prevalence of use of CBD for non-medical use amongst young people ( below 18 years of age)

There has been asignificant increase

in use

There has been aslight increase in

useThere has been no

change in use

There has been aslight decrease in

use

There has been asignificant decrease

in use

Non-medical use byadults

Non-medical use byyoung people (belowage 18)

Comments:

27. How would you describe the number of users CBD for non-medical use over the last 3 years in yourcountry?

Public health impact of use: Primary Care


28. Does your country collect data about presentations to primary care settings due to the use of CBD?

Yes

No

Unsure

Primary Care II


Number ofpresentations relating tosubstance alone

Number ofpresentations relating tosubstance in combinationwith other substances

Year of data collection

29. Number of primary care presentations relating to CBD

30. Does your country collect data about presentations to emergency care settings due to the use ofCBD?

Yes

No

Unsure

Public health: Emergency settings


Relating to substancealone:

Relating to substance withother substances:


31. Number of individuals in the past year presenting to emergency settings relating to the use of CBD

32. Please list the adverse effects presented for CBD at the emergency room/department

Injuries related to impaired driving

Injuries related to accidents/falls

Prenatal exposure

Cannabis use disorders / withdrawal

Psychiatric comorbidity

Respiratory problems

33. Does your country collect data about presentations to substance misuse treatment settings due tothe use of CBD?

Yes

No

Unsure

Public health: Substance misuse treatment


Relating to substancealone

Relating to substance andother substances


34. Number of individuals in the past year presenting to substance misuse treatment due to CBD

35. Does your country collect data about calls to poison centres due to the use of CBD?

Yes

No

Unsure

Public health impact: Poison control centres


Relating to substancealone

Relating to substance andother substances:


36. Number of calls to poison control centres due to the use of CBD

37. Does your country collect data about cases of impaired driving due to the use of CBD?

Yes

No

Unsure

Public health impact: Impaired driving


Relating tosubstance alone

Relating to substance andother substances

38. Number of cases of impaired driving due to CBD

This section will ask you about your national policies on the non-medical use of cannabis

Non-Medical Use: National legislation


Yes, my country has changed its legislation No, my country has not changed its legislation

CBD


39. In the past 3 years, has your country changed its national legislation around access to CBD fornon-medical use?

40. If yes, what types of legislative changes has your country made for non-medical use of CBD?

Yes, my country is preparing changes in its

legislationNo, my country is not preparing changes in its

legislation

Cannabis plant andcannabis resin


41. Is your country currently considering changes to its national legislation around access to CBD fornon-medical use?

There would be/has been asignificantly

negative impacton public health

There would be/has been a

slightly negativeimpact on public

health

There would be/has been no

impact on publichealth

There would be/has been a

slightly positiveimpact on public

health

There would be/has been asignificantly

positive impacton public health

Don't know/unsure

Increased availability fornon-medical use

Decreased availability fornon-medical use


42. In your opinion, how do you feel the changed legislation around access to CBD for non-medicaluse would impact / has already impacted public health in your country?

In this section, you may provide any additional information that you wish for the WHO ExpertCommittee to consider. You can provide comments on cannabis substances for medical non-medical and medical use. You may also wish to upload data or documents for the committee to consider. This may includeresults of national surveys. For the transmission of sensitive or highly confidential information,please submit these documents directly to the ECDD at [email protected]

Additional comments / information


43. Comments

No file chosen

44. File upload

Choose File

No file chosen

45. File upload

Choose File

No file chosen

46. File upload

Choose File

Date post:	10-Aug-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Introduction WHO ECDD Questionnaire: Cannabidiol (CBD) · Nomenclature Regulations 1967, etc.), the...

Documents